LPL Financial
CRSP icon

LPL Financial’s CRISPR Therapeutics CRSP Stock Holding History

LPL Financial’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-5,800
Closed -$376K – 5911
2025
Q3 		$376K Sell
5,800
-800
-12% -$45.9K ﹤0.01% 4866
2025
Q2 		$321K Buy
6,600
+100
+2% +$3.87K ﹤0.01% 4728
2025
Q1 		$221K Buy
+6,500
New +$276K ﹤0.01% 4793

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

LPL Financial's CRSP Position: Q1 2026 in Review

LPL Financial reduced its CRISPR Therapeutics (CRSP) stake by 11% in Q1 2026, selling an estimated $991K and leaving 152,042 shares worth $7.23M. The position accounts for ﹤0.01% of the portfolio, ranked #2297.

LPL Financial first reported a position in CRSP in Q1 2018 and has held it in 33 quarters since. The position peaked at $13.7M in Q3 2025. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • LPL Financial held 152,042 shares of CRISPR Therapeutics worth $7.23M as of Q1 2026.
  • LPL Financial sold 18,789 CRISPR Therapeutics shares in Q1 2026, an estimated $991K.
  • CRISPR Therapeutics made up ﹤0.01% of LPL Financial's portfolio in Q1 2026, its #2297 holding.
  • LPL Financial first reported a position in CRISPR Therapeutics in Q1 2018 and has held it in 33 quarters since.
  • LPL Financial's CRISPR Therapeutics position peaked at $13.7M in Q3 2025.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on LPL Financial's 13F filing for Q1 2026, filed 6 May 2026.